Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Diabetes Publish Ahead of Print published online ahead of print October 17, 2007
DOI: 10.2337/db07-0832

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db07-0832v1
57/1/64    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, M. S.
Right arrow Articles by Rodrigues, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, M. S.
Right arrow Articles by Rodrigues, B.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

Acute diabetes moderates trafficking of cardiac lipoprotein lipase through p38 MAPK dependent actin cytoskeleton organization

Min Suk Kim, Girish Kewalramani, Prasanth Puthanveetil, Vivian Lee, Ujendra Kumar, Ding An, Ashraf Abrahani, and Brian Rodrigues

Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, The University of British Columbia, 2146 East Mall, Vancouver, BC, Canada V6T 1Z3

Objective.: Heart disease is a leading cause of death in diabetes, and could occur due to excessive utilization of fatty acid (FA) for energy generation. Our objective was to determine the mechanisms by which AMPK augments cardiac lipoprotein lipase (LPL), the enzyme that provides the heart with majority of its FA.

Research Design and Methods.: We used diazoxide (DZ) in rats to induce hyperglycemia, or AICAR and thrombin to directly stimulate AMPK and p38 MAPK respectively in cardiomyocytes.

Results.: There was a substantial increase in LPL at the coronary lumen following 4 h of DZ. In these diabetic animals, phosphorylation of AMPK, p38 MAPK, and Hsp25 produced actin cytoskeleton rearrangement to facilitate LPL translocation to the myocyte surface, and eventually the vascular lumen. AICAR activated AMPK, p38 MAPK, and Hsp25 in a pattern similar to that seen with diabetes. AICAR also appreciably enhanced LPL, an effect reduced by pre-incubation with the p38 MAPK inhibitor SB202190, or cytochalasin D that inhibits actin polymerization. Thrombin activated p38 MAPK in the absence of AMPK phosphorylation. Comparable to diabetes, activation of p38 MAPK, and subsequently, Hsp25 phosphorylation and F-actin polymerization corresponded with an enhanced LPL activity. SB202190 and silencing of p38 MAPK also prevented these effects induced by thrombin and AICAR respectively.

Conclusions.: We propose that AMPK recruitment of LPL to the cardiomyocyte surface (which embraces p38 MAPK activation and actin cytoskeleton polymerization) represents an immediate compensatory response by the heart to guarantee FA supply when glucose utilization is compromised.


Correspondence: rodrigue{at}interchange.ubc.ca

Key Words: Heart • Fatty Acids • AMPK • Hsp25 • AICAR


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.